USP is exploring how its extensive expertise in developing quality standards for drug products and ingredients can contribute to pharmaceutical continuous manufacturing.
You might also like...
// May 24, 2023
World Vaccine Congress 2023: Spotlight shines on mRNA and viral vectored technology p...
Interest in innovative vaccines that use messenger ribonucleic acid (mRNA) and viral vectored technologies was among the key draws at this year’s World Vaccine Congress (WVC) on April 3-6 in Washington, D.C.
// April 17, 2023
USP’s Preferential Access for Regulators (PAR) Program: Supporting the Global Supply ...
In the U.S. and around the world, quality standards developed by the U.S. Pharmacopeia (USP) support the availability of safe, quality medicines, regulatory efficiencies, and a strong global medicine supply chain.
// March 07, 2023
Nitrosamine Impurities: Latest USP Tool Further Aids Understanding and Control...
USP has launched the newest tool in our suite of solutions to address the evolving nitrosamines crisis: the Nitrosamines Analytical Hub, a public, web-based repository of downloadable analytical procedures to test for nitrosamine impurities and related substances in pharmaceuticals.
